Figure 1.

Tofacitinib treatment was associated with enhanced bacterial growth and pathology in mouse lungs. A, The paucibacillary model of latent tuberculosis. Mycobacterium tuberculosis H37Rv log₁₀ colony-forming unit (CFU) counts in the lungs of bacille Calmette-Guérin (BCG)–vaccinated (Tuberculosis/BCG) and unvaccinated (Tuberculosis) mice. Error bars represent standard deviation. B, The impact of tofacitinib treatment on M. tuberculosis growth. M. tuberculosis H37Rv log₁₀ CFU counts in the lungs of mice from vaccinated mice that were untreated (Tuberculosis/BCG), treated with 1.5 mg/kg/day (Tuberculosis/BCG/Low Dose), or treated with 15 mg/kg/day (Tuberculosis/BCG/High Dose). Error bars represent standard deviation. C, Gross pathology of mouse lungs from each treatment group. D, Representative histopathology sections from mouse lungs from each treatment group, stained using hematoxylin and eosin.